Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TPO-RA

Phase 2Small molecule

IInstitute of Hematology & Blood Diseases Hospital, China

TPO-RA is one of 72 small molecule programs targeting Thrombocytopenia. It is currently in Phase 2.

4

Indications

4

Total Trials

3

Active Trials

71

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Primary Immune Thrombocytopenia (ITP)Recruiting

ITP - Immune ThrombocytopeniaNot yet recruiting

ThrombocytopeniaPhase 2

Active, not recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Primary Immune Thrombocytopenia (ITP)Phase 2

Recruiting

ITP - Immune ThrombocytopeniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

135 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Rysodeg

Cellcept

Vyvgart

Doptelet

Fabhalta

Johnson & Johnson

Wayrilz

GGenzyme, a Sanofi Company

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Tamiflu

CConrado Roberto Hoffmann Filho

Avlosulfon

AAlmirall, S.A.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

ITP - Immune Thrombocytopenia

NCT07669675

Q3 2030

Phase 2Recruiting

Primary Immune Thrombocytopenia (ITP)

NCT07421167

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT04890041·100 enrolled

Thrombocytopenia1 trial

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT05350956·60 enrolled

Primary Immune Thrombocytopenia (ITP)1 trial

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

Recruiting· Novartis logo

Novartis·Phase 2·NCT07421167·164 enrolled

ITP - Immune Thrombocytopenia1 trial

TPO-RA Plus Baricitinib vs. TPO-RA in Patients With ITP : A Randomized, Open-label Trial

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07669675·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TPO-RA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TPO-RA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TPO-RA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Related News